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Introduction
Glioblastoma multiforme (GBM) is one of the most incurable forms of human cancers. Its five-year survival rate is less than 3% [1] . Because of its highly invasive nature, not only surgical therapy but also adjuvant chemoradiotherapy is indispensable. In 1990s, a new drug temozolomide (TMZ) emerged [2] . TMZ chemotherapy concomitant with radiotherapy has been reported to make statistically significant prognostic progress in GBM patients, and thus it has become the first line chemoradiotherapy regimen for treatment of GBM [3] . TMZ is an alkylating agent that methylates the O 6 position of guanines. The formation of O 6 -methyl guanine leads to mismatch with thymine during DNA replication, eventually resulting in cell death. These methyl adducts are removed by a DNA repair enzyme, O 6 -methyl guanine methyltransferase (MGMT) [4] . High level of MGMT activity in cancer cells creates a resistant phenotype by blunting the effect of TMZ. Accordingly, epigenetic silencing of the MGMT gene by promoter methylation compromises DNA repair in cancer cells and is associated with better prognosis [5] . However, little is known about acquired TMZ resistance, which is a serious impediment in the treatment of GBM.
Micro RNAs (miRNAs) are approximately 22 bases long, non-coding and single-stranded regulatory RNAs that are found in both plants and animals [6] . Mature miRNA binds to target messenger RNA (mRNA) and induces its cleavage or translational repression depending on the degree of complementarity [7] . Although hundreds of miRNAs have been already cloned, only a part of them has been characterized. Several miRNAs have been shown to participate in cell proliferation or apoptosis in various types of cancers. miR-15a and miR-16 have been reported to induce apoptosis by targeting BCL2 [8] , and they are frequently deleted or underexpressed in chronic lymphocytic leukemia, prostate cancer and pituitary adenoma [9] [10] [11] . Reduced let-7 expression has been identified in lung cancer with poor prognosis [12] and inversely correlated with expression of RAS protein [13] . Compared to these underexpressed miRNAs, miR-17-92 cluster has an anti-apoptotic function and is overexpressed in lung cancer, B-cell lymphoma and anaplastic thyroid cancer [14] [15] [16] .
Knockdown of miR-17-3p in anaplastic thyroid cancer cells induced caspase activation, resulting in apoptotic cell death [16] . As mentioned above, miRNAs can act as both tumor suppressor and oncogene.
Distinct miRNA expression patterns have also been reported in GBM. The functional significance of some of these up-or down-regulated miRNAs has been identified so far. For example, miR-21, one of the best characterized cancer-associated miRNAs, is highly expressed in GBM and has multi-faced functions such as inhibition of apoptosis and growth promotion [17, 18] . miR-221 and miR-222 are other up-regulated miRNAs in GBM [19] [20] [21] .
These miRNAs have been thought to affect cell cycle by targeting CDKN1B and CDKN1C.
miR-128 has been identified as one of the most frequently down-regulated miRNAs in GBM.
It has been demonstrated that miR-128 targets Bmi-1 and then reduces cellular proliferation and also self-renewal of glioma stem cells [22] . As described above, miRNAs play a variety of oncogenic roles in GBM; however, there is no report regarding the relationship between drug resistance and miRNAs in GBM. It is likely that miRNAs can also modulate sensitivity to anti-cancer drug and induce resistance. In fact, there were significant correlations between miRNA expression pattern and compound potency using the NCI-60 cancer cell panel [23] . In the present study, therefore, we used TMZ-sensitive GBM cell lines to generate TMZ-resistant variants by continuous exposure to the drug. We then performed comprehensive analysis of miRNA expression using miRNA microarray to explore the mechanisms of acquired resistance against TMZ.
Materials and Methods

Cell culture and reagent
We used GBM cell lines of human origin: U251MG, U87MG, M059K and M059J, which are sensitive to TMZ. These were purchased from American Type Culture Collection (Manassas, VA, USA). All cells were maintained in DMEM supplemented with 5% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA) and 1% penicillin/streptomycin at 37ºC in a humidified atmosphere with 5% CO 2 . TMZ was purchased from WAKO Pure Chemical Industries (Osaka, Japan).
Cell survival assay
Cells (5×10 2 cells) were plated in each well of 96-well plates and treated with or without TMZ for 7 days. After incubation, a water-soluble tetrazolium salt (WST)-based assay was performed using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) according to the manufacturer's instruction. Optical densities were measured at 450 nm in a microplate reader
ImmunoMini NJ-2300 (System Instruments, Tokyo, Japan).
Methylation-specific PCR
DNA methylation patterns in the promoter region of the MGMT gene were analyzed by methylation-specific PCR as previously described [24, 25] 
miRNA microarray and cDNA microarray
Total RNAs were extracted from U251MG and U251 TMZ-resistant (U251R) cells using mirVana miRNA Isolation kit (Applied Biosystems/Ambion, Austin, TX, USA). Three hundred nanograms of the total RNA were subjected to Agilent miRNA microarray analysis service (Bio Matrix Research, Nagareyama, Japan). The array contained 556 probes for mature miRNAs. Specificity of this array is excellent and basically is capable of discriminating single base difference. Probes with "1" flag score in both samples were used for data analyses (264 probes). One microgram of the total RNAs was also subjected to Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray analysis service (Bio Matrix Research). The array contained 54,675 probes for mRNAs. Probes with "present call" flag score in both samples were used for data analyses (22,075 probes).
Real-time reverse transcription-polymerase chain reaction (RT-PCR) for miRNA
The quantitative real-time RT-PCR for miRNA was performed using TaqMan MicroRNA Assays (Applied Biosystems, Foster City, CA, USA). Briefly, 10 ng of total RNA was reverse transcribed using a specific looped RT primer for each miRNA using a corresponding TaqMan Real-time System (TaKaRa Bio). The cycle threshold value, which was determined using second derivative, was used to calculate the normalized expression of the indicated miRNAs using Q-Gene software [26] .
miRNA loss of functional analysis using LNA/DNA oligonucleotides
Locked nucleic acid (LNA) and deoxyribonucleic acid (DNA) hybrid (LNA/DNA) oligonucleotides (miR inhibitors) were designed using LNA design web tool, IDT SciTools (http://test.idtdna.com/analyzer/Applications/lna/) and chemically synthesized by Gene Design
Inc. (Osaka, Japan). LNA bases were inserted to increase specificity for the target as previously described [27] . hours, the cells were detached by trypsinization, and the cell number was counted using a
Coulter counter (Beckman Coulter, Fullerton, CA, USA) as the manufacturer's instruction.
Statistical analysis
Differences between groups were examined for statistical significance using ANOVA followed by Tukey's post test. P-value not exceeding 0.05 was considered statistically significant. Data were analyzed with PRISM version 4 software (GraphPad Software, La Jolla, CA, USA).
Results
Generation of TMZ-resistant cell lines
First of all, U251MG wild type (U251Wt) cells were exposed to 100 M TMZ for two weeks to generate TMZ-resistant variant. The majority of the cells died, but a small population survived and propagated. We then selected surviving colonies and established U251MG
TMZ-resistant cells (U251R). Their chemosensitivity was evaluated by water-soluble tetrazolium salt (WST)-based assay, and U251R cells displayed apparent resistance to TMZ as compared to U251Wt cells (Fig. 1A) . Similarly, we established U87R, M059KR and M059JR cells from U87MG, M059K and M059J cells, respectively (data not shown).
MGMT promoter methylation status in U251Wt and U251R cells
To determine whether MGMT expression is responsible for the acquired resistance in U251R cells, methylation status of the MGMT promoter was assessed by methylation-specific PCR.
As shown in Fig. 1B , the promoter region was fully methylated in both U251Wt and U251R
cells. In addition, we also examined MGMT mRNA expression by real-time RT-PCR. The
MGMT expression in both U251Wt and U251R cells was hardly detectable, compared to that in U138 cells (positive control). These data suggest that MGMT expression is not involved in the acquisition of TMZ resistance in U251MG cells.
Distinct miRNA expression pattern in GBM cells
To identify miRNAs specifically deregulated in U251R cells, we performed a comprehensive analysis of miRNA expression in U251Wt and U251R cells using miRNA microarrays.
Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0. (Fig. 2) , suggesting that up-regulation of those miRNAs is involved in the acquisition of TMZ resistance in GBM cells.
Loss of functional analysis using LNA/DNA oligonucleotides
To determine the biological function of those up-regulated miRNAs, we knocked down each miRNA using specific miR inhibitors (LNA/DNA hybrid oligonucleotides, see Materials and
Methods section) and investigated cell killing effect in U251R cells. Knockdown of miR-455-3p or miR-10a* did not show difference from LNA control (transfection control) or TMZ treatment alone; however, combined treatment with both LNA-455-3p or LNA-10a* and TMZ showed modest cell killing effect (Fig. 3A) . On the other hand, miR-195 knockdown alone showed moderate growth inhibition, and, moreover, combination with TMZ strongly enhanced cell death (Fig. 3A) .
Since miR-195 up-regulation in M059JR cells was not clear (Fig. 2) , we also performed knockdown experiments in M059JR cells. As shown in Fig. 3B , knockdown of miR-455-3p
and miR-10a* showed similar results. However, knockdown of miR-195 alone strongly induced cell killing effect, and combination with TMZ did not make significant differences (Fig. 3B) (although there was a tendency of enhancement). These data suggest that miR-195 is not involved in the acquisition of TMZ resistant in M059J cells. Taken together, inhibition of those miRNAs, at least in part, successfully reversed TMZ resistance in GBM cells.
In silico identification of possible targets and cDNA microarray analysis
To explore the mechanisms by which those miRNAs regulate TMZ resistance, three web-based databases, miRanda [28] , TargetScan [29] and PicTar [30] , were used to find (Fig. 4 ).
miRNAs were initially proposed to mediate translational repression of their target mRNAs.
However, it has been recently demonstrated that this is often accompanied by decrease in mRNA abundance itself [31, 32] . Therefore, transcriptional profiling is a useful means to identify potential miRNA targets. We therefore performed a cDNA microarray analysis using total RNA extracted from U251Wt and U251R cells. A comprehensive analysis of this microarray data will be reported elsewhere. Here we attempted to identify target genes which were actually down-regulated. Among possible targets selected using the above-mentioned databases, genes that were down-regulated (<0.8-fold) in the cDNA microarray data are shown in Table 2 . Ten genes for miR-195, 15 genes for miR-455-3p and 15 genes for miR-10a* were selected. We further performed a literature search using PubMed and Online Mendelian Inheritance in Man (OMIM) and selected promising candidate targets (Table 3) .
Discussion
TMZ has improved the prognosis of GBM patients [3, 5] ; however, almost all of them die of recurrence after chemoradiotherapy. We first assessed whether the TMZ resistance in U251R cells depends on epigenetic silencing of the MGMT promoter, the most well-known drug resistant mechanism in GBM. In our data, methylation status of the promoter region was not changed (fully methylated in both U251Wt and U251R cells), suggesting that MGMT expression is not involved in the acquired TMZ resistance in GBM. This is consistent with a previous report by Auger et al. [33] in which SNB-19 glioma cells and their resistant variants were used. Other mechanism may be involved in the step of obtaining the resistance.
In the present study, miR-455-3p, miR-195 and miR-10a* were up-regulated in U251R cells compared to parental U251Wt cells. There seems to be only one published paper about miR-455-3p. Guled et al. [34] showed that miR-455-3p was up-regulated in smoker group of malignant mesothelioma patients compared to non-smoker group. Its function, however, remains to be further examined. Regarding miR-10*, there is no report at the present time.
Compared to the two above-mentioned miRNAs, a greater number of reports about miR-195 have been published so far. miR-195 was reported to be up-regulated in cardiac hypertrophy, and transgenic mice overexpressing miR-195 resulted in cardiac growth with disorganization of cardiomyocytes [35] . Ji et al. [36] reported that miR-195 was highly expressed in rat carotid artery and down-regulated in the process of wound healing caused by balloon injury (see its supplemental data). The Neurogenin3 transcript is targeted by miR-195, which contributes to islet cell regeneration in pancreas [37] . These data indicate that miR-195 plays a variety of roles in different diseases. In oncology reports, miR-195 has been considered as tumor suppressor and/or inhibitor of cell proliferation. miR-195 is down-regulated in tongue squamous cell carcinoma [38] , primary peritoneal carcinoma [39] , bladder cancer [40] , gastric cancer [41] , and hepatocellular carcinoma cells [42] . However, in our present study, inhibition Since the recent evidences have suggested that mRNA abundance is also affected by miRNA [31, 32] , we combined in silico analysis of predicted targets of those miRNAs with cDNA microarray data to select the possible target genes (Table 3) . Among these candidates, three genes (SIAH1, WEE1 and RANBP3), which are possible targets of miR-195, seem to be promising. SIAH1, an E3 ubiquitin ligase, was underexpressed in breast cancer compared to normal tissue, and low level of its expression correlated with decreased probability of disease-free survival [44] . SIAH1 is a p53 target gene and contributes to p53-mediated cell cycle arrest through -catenin pathway [45] . Moreover, SIAH1 down-regulates MDR/P-glycoprotein expression and sensitizes the multidrug-resistant cells to chemotherapeutic agents [46] . Hara et al. [47] demonstrated that SIAH1 mediates apoptotic cell death by its binding to GAPDH. WEE1, a cell cycle regulator, inhibits G 2 /M transition and blocks cell division. Knockdown of WEE1 promotes G2/M progression and sensitizes stathmin-overexpressing breast cancer cells to paclitaxel and vinblastine [48] . RANBP3 ablation causes overactivation of Wnt signaling pathway, and the chromosome region 19p13.3
containing the RANBP3 gene is deleted in various types of cancers and may contain tumor suppressor gene [49] . Three promising genes (LTBR, EI24 and SMAD2) were identified as targets of miR-455-3p. LTBR, a proapoptotic gene, was down-regulated in busulfan-resistant human myeloid leukemia cells compared to sensitive cells [50] . EI24, a p53-target gene, was lost in invasive breast cancers, and knockdown of EI24 conferred resistance to etoposide treatment in breast cancer cells [51] . SMAD2 expression is lower in glioma cells than in normal astrocytes [52] . Similarly, two genes (EPHX1 and BRD7) are promising targets of miR-10a*. EPHX1 expression was higher in BCNU-resistant L1210 leukemia cells than in sensitive cells. BRD7, a putative tumor suppressor, interacted with BLOS2 and selectively suppressed transcription of E2F3 and cyclin A.
Since it has been demonstrated that each miRNA can have hundreds of mRNA targets, the mechanism of acquisition of the resistance might be the consequence of deregulation of several hundreds of mRNAs/proteins even though the change in each expression is less prominent. Presumably, such an integral change in mRNA/protein may cooperate to create a TMZ-resistant phenotype in our setting. In four established resistant variants, those miRNAs were consistently up-regulated (except miR-195 in M059JR cells), suggesting that this common mechanism may be shared, at least in part, in GBM cells. Importantly, in the present study, our miR inhibitors (LNA/DNA hybrid oligonucleotides) successfully reversed TMZ resistance in U251R cells, likely due to change of many target gene expressions including the above mentioned. Further study is needed to identify definite target gene sets.
In conclusion, our results demonstrate that miR-195, miR-455-3p and miR-10a* , at least in part, may play a role in acquired TMZ resistance in GBM cells, and miR inhibitors against these miRNAs can reverse the resistance. Corresponding miR inhibitors could be a novel therapeutic approach to recurrent GBM after treatment with TMZ. 
